WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 43'0801 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 38'8511 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 64'395  64'121  63'845  63'562  63'268  59'387  56'943  54'053 
Births 782  785  787  788  789  751  745  747 
Surviving infants 780  782  784  786  787  748  739  739 
Pop. less than 5 years 3'927  3'934  3'938  3'938  3'933  3'674  3'786  3'642 
Pop. less than 15 years 11'903  11'867  11'818  11'756  11'687  11'159  11'309  11'946 
Female 15-49 years 13'961  14'018  14'078  14'133  14'182  14'406  14'118  12'863 

Number of reported cases

(Click for retrospective incidence data for France)
Diphtheria
ChartChart
  14 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  157  267  272  14'949  10'000  1'244 
Mumps
ChartChart
  17'400 
Pertussis
ChartChart
  36  84  165  100 
Polio*
ChartChart
  10 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  10  26  33  208 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for France)
Vaccine year result method % card seen                                                
BCG          83  74 
DTP1          99  99  99  99 
DTP3          99  99  99  99  97  94 
DTP4          91 
IPV1         
HepB_BD         
HepB3          82  74  78  74  26 
Hib3          98  98  98  98  86 
JapEnc         
MCV1          90  89  90  89  84  71 
MCV2          74  67  72  67 
PCV1          95  95  96 
PCV3          89  89  89  89 
Pol3          99  99  99  99  98  95 
Rota1         
RotaC         
Rubella1          90  89  90  89 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for France)
BCG
ChartChart
  83  74  80 
DTP1
ChartChart
  99  99  99  99  99  99  97  92 
DTP3
ChartChart
  98  98  99  99  99  97  94  79 
HepB3
ChartChart
  83  83  74  78  74  26 
HepB_BD
ChartChart
 
Hib3
ChartChart
  97  97  98  98  98  86 
MCV1
ChartChart
  91  91  89  90  89  84  71 
MCV2
ChartChart
  77  77  67  72  67 
PCV3
ChartChart
  89  89  89  89  89 
Pol3
ChartChart
  98  98  99  99  99  98  95  80 
RCV1
ChartChart
  91  91  89  90  89  84  71 
RotaC
ChartChart
 

Number of districts in the country 101  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes Infant at risk
DTaPHibHepIPV 2, 4, 11 months; Yes
DTaPIPV 6 years; Yes
HPV 11-14 years (x2 doses); Yes Girls
Influenza_Adult Yes elderly, pregnant women, health care workers, adults with chronic disease and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12, 16-18 months; Yes
MenC_conj 12 months; Yes
Pneumo_conj 2, 4, 11 months; Yes
Pneumo_ps > 2 years; Yes population at risk
TdaPIPV 11-13, 25 years; Yes
Varicella 12-18 years; If no disease history . For specific at risk-groups only. 2 doses
YF 12 months, No French Guyana

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No   
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 101  101  101  101  100  100  100 
Nº districts with DTP3 coverage >=80% number     89         
% of districts with DTP3 coverage >=80% From 0 to 100%     88         
Nº districts with measles (MCV1) coverage >=95% number           NA 
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  No  No    Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.